CJ Bioscience, Inc (311690) Fair Value & Analysis
Healthcare · KR · Market cap 63.9B KRW
Fair value as of: Jun 24, 2026
Analysis
CJ Bioscience, Inc (311690) currently trades at 4,400 KRW, while our model-based Fair Value estimate is 7,390 KRW — implying the stock looks roughly 67.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics analysis portal for microbial research; EzBioCloud Pro, a next-generation analysis platform for infection diagnosis and microbial bioinformatics analysis; Gut Inside, a microbiome testing service; and TrueBac ID, a cloud-based service platform that can identify various bacterial species based on genomic data. The company was formerly known as ChunLab, Inc. and changed its name to CJ Bioscience, Inc. in December 2021. CJ Bioscience, Inc. was fou…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CJ Bioscience, Inc (311690) undervalued?
What is the fair value of 311690?
What is the quality score of 311690?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.